Shukra Pharmaceuticals Limited (NSE:SHUKRAPHAR)

Market Cap	25.03B +82.9%
Revenue (ttm)	748.59M +91.9%
Net Income	339.87M +235.9%
EPS	0.81 +262.4%
Shares Out	n/a
PE Ratio	73.64
Forward PE	n/a
Dividend	0.01 (0.02%)
Ex-Dividend Date	Sep 21, 2026

Volume	3,447,764
Open	59.25
Previous Close	58.59
Day's Range	56.05 - 59.77
52-Week Range	40.06 - 59.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Shukra Pharmaceuticals

Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally. The company offers various products, such as antibiotics, anti biotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hy...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 115
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SHUKRAPHAR

Financial Performance

In fiscal year 2026, Shukra Pharmaceuticals's revenue was 567.27 million, an increase of 73.31% compared to the previous year's 327.32 million. Earnings were 220.58 million, an increase of 130.37%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 24, 2026

Data Sources Report a data error